NCT05094804 2023-11-02A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer AgentsOncoResponse, Inc.Phase 1/2 Unknown172 enrolled
NCT00154388 2016-11-18Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesNovartisPhase 2 Completed185 enrolled
NCT00526149 2013-10-07BI 2536 in Treating Patients With Recurrent or Metastatic Solid TumorsEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 2 Completed76 enrolled